Hemenway Trust Co LLC Sells 873 Shares of Becton, Dickinson and Company (NYSE:BDX)

Hemenway Trust Co LLC lowered its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 62,582 shares of the medical instruments supplier’s stock after selling 873 shares during the quarter. Becton, Dickinson and Company makes up 1.3% of Hemenway Trust Co LLC’s portfolio, making the stock its 27th biggest position. Hemenway Trust Co LLC’s holdings in Becton, Dickinson and Company were worth $14,626,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BDX. Lincoln National Corp raised its holdings in shares of Becton, Dickinson and Company by 7.4% in the 4th quarter. Lincoln National Corp now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,060,000 after purchasing an additional 299 shares in the last quarter. Gryphon Financial Partners LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $211,000. E Fund Management Co. Ltd. raised its stake in shares of Becton, Dickinson and Company by 29.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 1,014 shares of the medical instruments supplier’s stock worth $247,000 after acquiring an additional 230 shares in the last quarter. Wealthspire Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 9.4% during the 4th quarter. Wealthspire Advisors LLC now owns 8,780 shares of the medical instruments supplier’s stock worth $2,141,000 after acquiring an additional 755 shares in the last quarter. Finally, Montag A & Associates Inc. raised its stake in shares of Becton, Dickinson and Company by 3.3% during the 4th quarter. Montag A & Associates Inc. now owns 5,070 shares of the medical instruments supplier’s stock worth $1,236,000 after acquiring an additional 160 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded down $1.04 during mid-day trading on Friday, reaching $232.21. 158,506 shares of the stock were exchanged, compared to its average volume of 1,424,132. The business’s 50 day moving average is $234.09 and its 200-day moving average is $236.02. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The company has a market capitalization of $67.11 billion, a P/E ratio of 51.35, a P/E/G ratio of 1.98 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the prior year, the firm posted $2.96 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts forecast that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Wall Street Analyst Weigh In

BDX has been the subject of several recent analyst reports. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI dropped their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price on the stock. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.